These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33809310)

  • 21. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
    Facca VJ; Al-Saden N; Ku A; Reilly RM
    Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
    Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folate Receptor α-Targeted
    Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
    Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
    J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-in-Human Evaluation of Site-Specifically Labeled
    Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
    J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
    Connolly RM; Leal JP; Goetz MP; Zhang Z; Zhou XC; Jacobs LK; Mhlanga J; O JH; Carpenter J; Storniolo AM; Watkins S; Fetting JH; Miller RS; Sideras K; Jeter SC; Walsh B; Powers P; Zorzi J; Boughey JC; Davidson NE; Carey LA; Wolff AC; Khouri N; Gabrielson E; Wahl RL; Stearns V
    J Nucl Med; 2015 Jan; 56(1):31-7. PubMed ID: 25476537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
    Chen Y; Wang L; Liu H; Song F; Xu C; Zhang K; Chen Q; Wu S; Zhu Y; Dong Y; Zhou M; Zhang H; Tian M
    Mol Imaging Biol; 2018 Apr; 20(2):309-317. PubMed ID: 28795272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy de-escalation using an
    Pérez-García JM; Gebhart G; Ruiz Borrego M; Stradella A; Bermejo B; Schmid P; Marmé F; Escrivá-de-Romani S; Calvo L; Ribelles N; Martinez N; Albacar C; Prat A; Dalenc F; Kerrou K; Colleoni M; Afonso N; Di Cosimo S; Sampayo-Cordero M; Malfettone A; Cortés J; Llombart-Cussac A;
    Lancet Oncol; 2021 Jun; 22(6):858-871. PubMed ID: 34019819
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Bensch F; Brouwers AH; Lub-de Hooge MN; de Jong JR; van der Vegt B; Sleijfer S; de Vries EGE; Schröder CP
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2300-2306. PubMed ID: 30058029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours.
    Knight JC; Mosley MJ; Kersemans V; Dias GM; Allen PD; Smart S; Cornelissen B
    Nucl Med Biol; 2019 Mar; 70():14-22. PubMed ID: 30825614
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal [
    Gebhart G; Keyaerts M; Guiot T; Flamen P; Ruiz-Borrego M; Stradella A; Bermejo B; Escriva-de-Romani S; Calvo Martínez L; Ribelles N; Fernandez-Abad M; Albacar C; Colleoni M; Garrigos L; Atienza de Frutos M; Dalenc F; Prat A; Marmé F; Schmid P; Kerrou K; Braga S; Gener P; Sampayo-Cordero M; Cortés J; Pérez-García JM; Llombart-Cussac A
    J Nucl Med; 2024 May; 65(5):708-713. PubMed ID: 38575192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of HER2 expression using
    Zhao L; Xing Y; Liu C; Ma S; Huang W; Cheng Z; Zhao J
    Breast Cancer Res; 2024 Mar; 26(1):40. PubMed ID: 38459598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
    Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
    Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D; Giacchetti S; Hatt M; Marty M; Vercellino L; de Roquancourt A; Cuvier C; Coussy F; Espié M; Hindié E
    Br J Cancer; 2013 Sep; 109(5):1157-64. PubMed ID: 23942075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
    J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.